FINANCIAL STATEMENTS 109 2 FINANCE INComE ANd ExpENSE CoNTINuEd The amount of exchange gains and losses recognised in income, other than those arising on financial instruments measured at fair value through profit or loss in accordance with IAS 39 see Note 16, is a loss of $12m 2007: $3m: 2006: $14m.
3 TAxATIoN Taxation recognised in the income statement is as follows: 2008 2007 2006 $m $m $m Current tax expense Current year 2,946 1,890 2,431 Adjustment for prior years 130 261 270 3,076 2,151 2,701 Deferred tax expense Origination and reversal of temporary differences 486 379 81 Adjustment to prior years 39 174 140 525 205 221 Total taxation expense in the income statement 2,551 2,356 2,480 Taxation has been provided at current rates on the profits earned for the periods covered by the Group Financial Statements.
The 2008, 2007 and 2006 prior period current tax adjustments relate mainly to tax accrual to tax return adjustments, an increase in provisions in respect of a number of transfer pricing audits and double tax relief.
The 2008, 2007 and 2006 prior year deferred tax credits relate to tax accrual to tax return adjustments and the recognition of previously unrecognised deferred tax assets.
To the extent that dividends remitted from overseas subsidiaries, joint ventures and associates are expected to result in additional taxes, appropriate amounts have been provided for.
No deferred tax has been provided for unremitted earnings of Group companies overseas as these are considered permanently employed in the businesses of these companies.
Unremitted earnings may be liable to overseas taxes and or UK taxation after allowing for double taxation relief if they were to be distributed as dividends.
The aggregate amount of temporary differences associated with investments in subsidiaries and branches for which deferred tax liabilities have not been recognised totalled approximately $8,449m at 31 December 2008 2007: $12,639m: 2006: $13,291m.
CoNSolIdATEd STATEmENT oF RECogNISEd INComE ANd ExpENSE The current tax credit on consolidation exchange adjustments taken to reserves amounted to $20m in 2008 2007: $32m: 2006: $62m.
The current tax credit on share-based payments amounted to $nil 2007: $1m: 2006: $36m.
The deferred tax credit taken to reserves amounted to $348m in 2008 2007: $nil: 2006: $39m.
FACToRS AFFECTINg FuTuRE TAx CHARgES As a group involved in worldwide operations, AstraZeneca is subject to several factors that may affect future tax charges, principally the levels and mix of profitability in different jurisdictions, transfer pricing regulations and tax rates imposed.
A number of material items currently under audit and negotiation are set out in detail in Note 25.
TAx RECoNCIlIATIoN To uk STATuToRy RATE The table shown below reconciles the UK statutory tax charge to the Groups total tax charge.
2008 2007 2006 $m $m $m Profit before tax 8,681 7,983 8,543 1 Notional taxation charge at UK corporation tax rate of 28.5% 30% for 2007, 30% for 2006 2,474 2,395 2,563 Differences in effective overseas tax rates 8 105 156 2 Deferred tax income relating to reduction in Swedish, UK and other tax rates 70 57 Unrecognised deferred tax asset 7 1 6 Items not deductible for tax purposes 119 70 58 Items not chargeable for tax purposes 48 33 109 Adjustments in respect of prior periods 91 87 130 Total tax charge for the year 2,551 2,356 2,480 1 The UK statutory tax rate was reduced from 30% to 28% effective from 1 April 2008 resulting in the effective tax rate for the Group for 2008 being 28.5%.
2 The 2008 item relates to the reduction in the Swedish statutory corporation tax rate from 28% to 26.3% effective from 1 January 2009.
The majority of the 2007 item relates to the reduction in the UK statutory corporation tax rate referred to above.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008 110 3 TAxATIoN CoNTINuEd dEFERREd TAx Deferred tax assets and liabilities and the movements during the year, before offset of balances within countries, are as follows: Losses Pension Interand tax Property, and postcompany Deferred credits plant and Intangible retirement inventory Untaxed Accrued Share capital carried 1 equipment assets benefits transfers reserves expenses schemes gains forward Other Total $m $m $m $m $m $m $m $m $m $m $m Deferred tax assets at 1 January 2007 37 2 604 853 323 113 57 28 2,017 Deferred tax liabilities at 1 January 2007 502 819 881 99 55 2,356 2 Net deferred tax balance at 1 January 2007 465 817 604 853 881 323 113 99 57 27 339 Income statement 130 201 99 71 225 190 45 12 96 58 205 Statement of recognised income and expense 8 8 3 Acquisition of subsidiary undertaking 3 2,973 58 74 369 29 2,498 Exchange 35 5 15 46 65 11 2 1 1 33 2 Net deferred tax balance at 31 December 2007 627 3,594 528 886 1,171 598 62 88 330 1 3,075 Deferred tax assets at 31 December 2007 66 59 531 907 611 62 330 71 2,637 Deferred tax liabilities at 31 December 2007 693 3,653 3 21 1,171 13 88 70 5,712 Net deferred tax balance at 31 December 2007 627 3,594 528 886 1,171 598 62 88 330 1 3,075 Income statement 122 375 24 55 119 37 43 12 24 525 Statement of recognised income and expense 340 9 1 348 Exchange 168 130 113 35 199 37 14 24 7 3 312 Net deferred tax balance at 31 December 2008 337 3,089 779 906 1,091 598 100 64 335 27 1,890 Deferred tax assets at 31 December 2008 136 42 786 935 598 100 335 45 2,977 Deferred tax liabilities at 31 December 2008 473 3,131 7 29 1,091 64 72 4,867 Net deferred tax balance at 31 December 2008 337 3,089 779 906 1,091 598 100 64 335 27 1,890 2008 2007 2006 Analysed in the balance sheet, after offset of balances within countries, as: $m $m $m Deferred tax assets 1,236 1,044 1,220 Deferred tax liabilities 3,126 4,119 1,559 Net deferred tax balance 1,890 3,075 339 1 Untaxed reserves relate to taxable profits where the tax liability is deferred to later periods.
2 During 2008, the Group carried out a review of its deferred tax balances resulting in a reclassification of a deferred tax liability of $284m from property, plant and equipment to intangible assets as at 31 December 2007 $328m as at 1 January 2007.
3 The deferred tax liability of $2,498m relates to MedImmune, Inc. and other acquisitions.
uNRECogNISEd dEFERREd TAx ASSETS Deferred tax assets of $80m have not been recognised in respect of deductible temporary differences 2007: $106m: 2006: $103m because it is not probable that future taxable profit will be available against which the Group can utilise the benefits therefrom.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008
